|
AGEN | Agenus Inc |
|
|
AGEN | Agenus Inc |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ -0.74 |
| Leverage | 252.37% |
| Market Cap | $ 1.3B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -194.7m |
| Margin | -183.82% |
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.